<?xml version='1.0' encoding='utf-8'?>
<document id="26596948"><sentence text="Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir."><entity charOffset="31-41" id="DDI-PubMed.26596948.s1.e0" text="Sofosbuvir" /><entity charOffset="96-105" id="DDI-PubMed.26596948.s1.e1" text="Dasabuvir" /><pair ddi="false" e1="DDI-PubMed.26596948.s1.e0" e2="DDI-PubMed.26596948.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26596948.s1.e0" e2="DDI-PubMed.26596948.s1.e1" /></sentence><sentence text="The combination of ombitasvir (an NS5A inhibitor), paritaprevir (an NS3/4A inhibitor) coadministered with ritonavir (r), and dasabuvir (an NS5B nonnucleoside polymerase inhibitor), referred to as the 3D regimen, and the combination of ombitasvir-paritaprevir-r, referred to as the 2D regimen, have demonstrated high efficacy with and without ribavirin in hepatitis C virus (HCV)-infected subjects"><entity charOffset="19-29" id="DDI-PubMed.26596948.s2.e0" text="ombitasvir" /><entity charOffset="51-63" id="DDI-PubMed.26596948.s2.e1" text="paritaprevir" /><entity charOffset="106-115" id="DDI-PubMed.26596948.s2.e2" text="ritonavir" /><entity charOffset="125-134" id="DDI-PubMed.26596948.s2.e3" text="dasabuvir" /><entity charOffset="342-351" id="DDI-PubMed.26596948.s2.e4" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e0" e2="DDI-PubMed.26596948.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e0" e2="DDI-PubMed.26596948.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e0" e2="DDI-PubMed.26596948.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e0" e2="DDI-PubMed.26596948.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e0" e2="DDI-PubMed.26596948.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e1" e2="DDI-PubMed.26596948.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e1" e2="DDI-PubMed.26596948.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e1" e2="DDI-PubMed.26596948.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e1" e2="DDI-PubMed.26596948.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e2" e2="DDI-PubMed.26596948.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e2" e2="DDI-PubMed.26596948.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e2" e2="DDI-PubMed.26596948.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e3" e2="DDI-PubMed.26596948.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26596948.s2.e3" e2="DDI-PubMed.26596948.s2.e4" /></sentence><sentence text=" These regimens have potential for coadministration with sofosbuvir (nucleoside NS5B inhibitor) in the treatment of HCV"><entity charOffset="57-67" id="DDI-PubMed.26596948.s3.e0" text="sofosbuvir" /></sentence><sentence text=" This phase 1, drug-drug interaction, open-label, multiple-dose study enrolled 32 healthy subjects to receive the 3D or 2D regimen in combination with sofosbuvir"><entity charOffset="151-161" id="DDI-PubMed.26596948.s4.e0" text="sofosbuvir" /></sentence><sentence text=" Doses of study drugs were as follows: ombitasvir-paritaprevir-r, 25/150/100 mg daily (QD); dasabuvir, 250 mg twice daily (BID); and sofosbuvir, 400 mg QD"><entity charOffset="92-101" id="DDI-PubMed.26596948.s5.e0" text="dasabuvir" /><entity charOffset="133-143" id="DDI-PubMed.26596948.s5.e1" text="sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.26596948.s5.e0" e2="DDI-PubMed.26596948.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26596948.s5.e0" e2="DDI-PubMed.26596948.s5.e1" /></sentence><sentence text=" Blood samples were collected on study days 7, 14, and 21 for evaluating drug interaction at steady state" /><sentence text=" The effect of the 3D and 2D regimens on the pharmacokinetics of sofosbuvir and its circulating metabolite GS-331007 and vice versa was assessed by a repeated-measures analysis"><entity charOffset="65-75" id="DDI-PubMed.26596948.s7.e0" text="sofosbuvir" /></sentence><sentence text=" Exposures of the 3D and 2D regimens were similar (â‰¤20% change) during coadministration with sofosbuvir and during administration alone"><entity charOffset="93-103" id="DDI-PubMed.26596948.s8.e0" text="sofosbuvir" /></sentence><sentence text=" Sofosbuvir exposures were 61% to 112% higher with the 3D regimen and 64% to 93% higher with the 2D regimen than with sofosbuvir alone"><entity charOffset="1-11" id="DDI-PubMed.26596948.s9.e0" text="Sofosbuvir" /><entity charOffset="118-128" id="DDI-PubMed.26596948.s9.e1" text="sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.26596948.s9.e0" e2="DDI-PubMed.26596948.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26596948.s9.e0" e2="DDI-PubMed.26596948.s9.e1" /></sentence><sentence text=" GS-331007 total exposures were 27% and 32% higher with the 3D and 2D regimens, respectively, than with sofosbuvir alone"><entity charOffset="104-114" id="DDI-PubMed.26596948.s10.e0" text="sofosbuvir" /></sentence><sentence text=" Increases in sofosbuvir and GS-331007 exposures likely resulted from breast cancer resistance protein (BCRP) and/or P glycoprotein (P-gp) transporter inhibition by paritaprevir and ritonavir"><entity charOffset="14-24" id="DDI-PubMed.26596948.s11.e0" text="sofosbuvir" /><entity charOffset="29-38" id="DDI-PubMed.26596948.s11.e1" text="GS-331007" /><entity charOffset="165-177" id="DDI-PubMed.26596948.s11.e2" text="paritaprevir" /><entity charOffset="182-191" id="DDI-PubMed.26596948.s11.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.26596948.s11.e0" e2="DDI-PubMed.26596948.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26596948.s11.e0" e2="DDI-PubMed.26596948.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26596948.s11.e0" e2="DDI-PubMed.26596948.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26596948.s11.e0" e2="DDI-PubMed.26596948.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26596948.s11.e1" e2="DDI-PubMed.26596948.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26596948.s11.e1" e2="DDI-PubMed.26596948.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26596948.s11.e1" e2="DDI-PubMed.26596948.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26596948.s11.e2" e2="DDI-PubMed.26596948.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26596948.s11.e2" e2="DDI-PubMed.26596948.s11.e3" /></sentence><sentence text=" No subjects discontinued the study due to study drug-related adverse events" /><sentence text=" No dose adjustment is recommended for 3D, 2D, or sofosbuvir in clinical trials exploring the safety and efficacy of the combination"><entity charOffset="50-60" id="DDI-PubMed.26596948.s13.e0" text="sofosbuvir" /></sentence><sentence text=" (This study has been registered at ClinicalTrials" /><sentence text="gov under registration no" /><sentence text=" NCT02356562 and NCT02292719" /><sentence text=")" /><sentence text=" " /></document>